Drawing for IMMAGINA BIOTECHNOLOGY THE RIBOSOME COMPANY

USPTO serial 79362445

IMMAGINA BIOTECHNOLOGY THE RIBOSOME COMPANY

Reviewed by CopyMark Law Group

Reg. 7435424Status 700Registered
Filing date
Status date
Registration date
Jul 9, 2024
Examiner
BLAZICH, JOAN MICHELE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with IMMAGINA BIOTECHNOLOGY THE RIBOSOME COMPANY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemical substances for analyses in laboratories, other than for medical or veterinary purposes, chemical for use in industry and natural elements, namely, radiative elements for scientific purposes; nucleic acid sequencing programs other than for medical use, namely, nucleic acid sequences and chemical reagents for other than medical or veterinary purposes; chemical compositions and materials for use in science, namely, chemicals for use in science; chemical reagent mixtures in kit form comprised of chemical reagents other than for medical or veterinary use; chemical reagents other than for medical or veterinary purposes for use in the field of scientific research; chemicals for use in performing nucleic acid polymerase chain reactions other than medical and veterinary purposes; chemical diagnostic reagents for industrial purposes, namely, cellular culture environments, cellular regulation agents, amino acids, dna fragments, rna fragments, dna probes, rna probes, material for genetic cloning, tagged antibodies for laboratory use; protein in raw material form for scientific and medical research; photosensitive chemicals being chemical preparations for use in photography; activators being chemicals for use in industry and scienceACTIVE
005Stem cells for medical purposes; chemico-pharmaceutical preparations for treating cancer; chemical preparations for medical purposes, namely, for treating cancer; chemical preparations for pharmaceutical purposes for the treatment of renal disease; diagnostic preparations for medical purposes, namely, for diagnosing cardiovascular conditions; pharmaceutical preparations for treating cancer; clinical diagnostic reagents being diagnostic reagents for medical use; diagnostic biomarker reagents for medical purposes; reagents for use in medical genetic testing; swabs for medical purposes; biological reagents for medical use; biotechnological preparations for medical use for treating cancer; antibodies, namely, colostral antibodies for medical purposes; regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes; enzymes for medical and veterinary purposesACTIVE
010Screening kit, namely, apparatus for DNA and RNA testing for medical purposes; biomedical diagnostic apparatus, namely, molecular diagnostic devices for medical purposes used for nucleic acid testing, infectious disease testing, genetic testing; biomedical devices in the nature of cartridges, unfilled, for medical purposes, for loading biological samples for use in molecular diagnostic devices; testing sample collection equipment, namely, swabs for obtaining biological samples from subjects for biomedical purposes; apparatus for dna and rna testing for medical purposes; apparatus for carrying-out diagnostic tests for medical purposes, namely, apparatus for DNA and RNA testing for medical purposes; screening kits for medical purposes, namely, apparatus for DNA and RNA testing for medical purposes; probes for medical purposes; sensor apparatus for medical use in diagnosis, namely, patient monitoring sensors and alarmsACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 5, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Dec 18, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB
Dec 17, 2024FIMPFINAL DISPOSITION PROCESSED
Oct 9, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 9, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 9, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 7, 2024ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 6, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED
Apr 23, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 23, 2024GPNXNOTIFICATION PROCESSED BY IB
Apr 23, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 3, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 3, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 14, 2024PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 14, 2024ALIEASSIGNED TO LIE
Mar 5, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Mar 5, 2024ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 27, 2024PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY
Feb 9, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Feb 9, 2024XAECEXAMINER'S AMENDMENT ENTERED
Feb 9, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 9, 2024GNEAEXAMINERS AMENDMENT E-MAILED
Feb 9, 2024CNEAEXAMINERS AMENDMENT -WRITTEN
Feb 2, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Feb 2, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 2, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 29, 2023RFNTREFUSAL PROCESSED BY IB
Aug 9, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 9, 2023RFRRREFUSAL PROCESSED BY MPU
Jul 4, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 3, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2023DOCKASSIGNED TO EXAMINER
Feb 27, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 27, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 27, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 27, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 27, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 27, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 15, 2023MAFRAPPLICATION FILING RECEIPT MAILED
Feb 11, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 9, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance